公开(公告)号：US20250042934A1

公开(公告)日：2025-02-06

申请号：US18581595

申请日：2024-02-20

Applicant: Sage Therapeutics, Inc.

Inventor： Gabriel Martinez Botella ,  Boyd L. Harrison ,  Albert Jean Robichaud ,  Francesco G. Salituro ,  Richard Thomas Beresis

IPC: C07J41/00 ,  A61K31/56 ,  A61K45/06 ,  C07J3/00 ,  C07J9/00 ,  C07J17/00 ,  C07J31/00 ,  C07J33/00 ,  C07J43/00

Abstract: Described herein are neuroactive steroids of the Formula (II): or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

公开(公告)号：US12180248B2

公开(公告)日：2024-12-31

申请号：US18169964

申请日：2023-02-16

Applicant: Sage Therapeutics, Inc.

Inventor： Gabriel Martinez Botella ,  Francesco G. Salituro ,  Albert Jean Robichaud ,  Boyd L. Harrison

IPC: C07J75/00 ,  A61K9/00 ,  A61K31/58 ,  A61P25/00 ,  C07D231/14 ,  C07D249/04 ,  C07D249/18 ,  C07D295/033 ,  C07J9/00 ,  C07J13/00 ,  C07J43/00

Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein, R1, R2a, R2b, R3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

公开(公告)号：US20240417423A1

公开(公告)日：2024-12-19

申请号：US18694572

申请日：2022-09-22

Applicant: SAGE THERAPEUTICS, INC.

Inventor： Maria-Jesus Blanco-Pillado

IPC: C07J9/00 ,  A61K31/575 ,  C07B59/00

Abstract: Deuterated compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. These compounds are contemplated as useful for the prevention and treatment of a variety of CNS-related conditions.

公开(公告)号：US20240309042A1

公开(公告)日：2024-09-19

申请号：US18616903

申请日：2024-03-26

Applicant: SAGE THERAPEUTICS, INC.

Inventor： Maria Jesus Blanco-Pillado ,  Francesco G. Salituro ,  Marshall Lee Morningstar

IPC: C07J43/00 ,  C07J41/00

CPC classification number: C07J43/003 ,  C07J41/0044 ,  C07J41/0094

Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b) N N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55c wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.

公开(公告)号：US20240270783A1

公开(公告)日：2024-08-15

申请号：US18532752

申请日：2023-12-07

Applicant: SAGE THERAPEUTICS, INC.

Inventor： Gabriel Martinez Botella ,  Boyd L. Harrison ,  Albert Jean Robichaud ,  Francesco G. Salituro

IPC: C07J9/00

CPC classification number: C07J9/00 ,  C07J9/005 ,  C07B2200/05

Abstract: Compounds are provided according to Formula (III):




and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R5, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

公开(公告)号：US20240252514A1

公开(公告)日：2024-08-01

申请号：US18289550

申请日：2022-05-04

Applicant: SAGE THERAPEUTICS, INC.

Inventor： James J. Doherty ,  Michael C. Quirk ,  Aaron Michael Koenig ,  Jason Karl Johannesen

IPC: A61K31/575 ,  A61P25/16 ,  A61P25/28

CPC classification number: A61K31/575 ,  A61P25/16 ,  A61P25/28

Abstract: Provided herein are methods for improving working memory and/or executive function in a subject suffering from Parkinson's Disease, comprising administering to the subject a compound having the formula.

公开(公告)号：US12048706B2

公开(公告)日：2024-07-30

申请号：US17592244

申请日：2022-02-03

Applicant: Sage Therapeutics, Inc.

Inventor： Kiran Reddy ,  Stephen J. Kanes

IPC: A61K31/10 ,  A61K9/00 ,  A61K9/107 ,  A61K31/57 ,  A61K31/573 ,  A61K45/06 ,  A61M5/20

CPC classification number: A61K31/573 ,  A61K31/57 ,  A61K45/06

Abstract: Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.

公开(公告)号：US20240245711A1

公开(公告)日：2024-07-25

申请号：US18550724

申请日：2022-03-17

Applicant: Sage Therapeutics, Inc.

Inventor： Robert Alfonso Lasser ,  James Doherty ,  Jeffrey Martin Jonas ,  Stephen Jay Kanes ,  Handan Gunduz-Bruce ,  Joi Lisa Dunbar ,  Bambang Senoaji Adiwijaya

IPC: A61K31/58 ,  A61P25/24

CPC classification number: A61K31/58 ,  A61P25/24

Abstract: The present disclosure relates to methods of treating major depressive disorder (MDD) in a subject in need thereof by (i) performing an initial treatment course on the subject comprising administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, and (ii) performing 0, 1, or 2 subsequent treatment courses on the subject, wherein each subsequent treatment course comprises administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, in response to a recurrence of depression symptoms. The 0, 1, or 2 subsequent treatment courses can be performed over a period of 12 months from the beginning of the initial treatment course.

公开(公告)号：US20240199682A1

公开(公告)日：2024-06-20

申请号：US18388390

申请日：2023-11-09

Applicant: Sage Therapeutics, Inc.

Inventor： Francesco G. Salituro ,  Albert Jean Robichaud ,  Gabriel Martinez Botella ,  Boyd L. Harrison ,  Andrew Griffin

IPC: C07J9/00 ,  A61P1/00 ,  A61P19/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/28 ,  A61P35/00 ,  C07J17/00 ,  C07J43/00

CPC classification number: C07J9/00 ,  A61P1/00 ,  A61P19/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/28 ,  A61P35/00 ,  C07J17/00 ,  C07J43/003

Abstract: Compounds are provided according to Formula (I):






and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein R2, R3, R4, R5, and and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

公开(公告)号：US20240150393A1

公开(公告)日：2024-05-09

申请号：US18328865

申请日：2023-06-05

Applicant: Sage Therapeutics, Inc.

Inventor： Albert Jean Robichaud ,  Francesco G. Salituro ,  Maria Jesus Blanco-Pillado ,  Daniel La ,  Boyd L. Harrison

IPC: C07J73/00

CPC classification number: C07J73/003

Abstract: Provided herein is a compound of Formula (I-I)




or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.